Search Result

Results for "

Lapatinib

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Autophagy (14) CDK (1) DNA/RNA Synthesis (1) Drug Metabolite (1) EGFR (16) Ferroptosis (14) GCGR (1) Isotope-Labeled Compounds (7) Parasite (1) PROTACs (1) Reference Standards (1) SARS-CoV (1)
By Research Areas:	Cancer (16) Infection (2)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50898

*Lapatinib* Maximum Cited Publications 81 Publications Verification GW572016; GW2016	EGFR Autophagy Ferroptosis	Cancer
Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898S

Lapatinib-d4 GW572016-d₄; GW2016-d₄	EGFR Autophagy Ferroptosis	Cancer
Lapatinib-d₄ is the deuterium labeled Lapatinib (HY-50898). Lapatinib is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898BR

Lapatinib ditosylate monohydrate (Standard)	EGFR Autophagy Ferroptosis	Cancer
Lapatinib (ditosylate monohydrate) (Standard) is the analytical standard of Lapatinib (ditosylate monohydrate). This product is intended for research and analytical applications. Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898AR

Lapatinib ditosylate (Standard)	EGFR Autophagy Ferroptosis	Cancer
Lapatinib (ditosylate) (Standard) is the analytical standard of Lapatinib (ditosylate). This product is intended for research and analytical applications. Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898R

Lapatinib (Standard) GW572016 (Standard); GW2016 (Standard)	Reference Standards EGFR Autophagy Ferroptosis	Cancer
Lapatinib (Standard) is the analytical standard of Lapatinib. This product is intended for research and analytical applications. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-W777297

Lapatinib-13C2,15N Ditosylate	Isotope-Labeled Compounds EGFR Autophagy Ferroptosis	Cancer
Lapatinib- ¹³C₂, ¹⁵N Ditosylate is the ¹³C- and ¹⁵N-labeled Lapatinib ditosylate (HY-50898A). Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-20390S

Lapatinib impurity 18-d4	Drug Metabolite Isotope-Labeled Compounds	Others
Lapatinib impurity 18-d₄ is deuterium labeled 3-Chloro-4-((3-fluorobenzyl)oxy)aniline.

HY-50898S2

Lapatinib-d5 GW572016-d₅; GW2016-d₅	Isotope-Labeled Compounds EGFR Autophagy Ferroptosis	Cancer
Lapatinib-d₅ is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898S1

Lapatinib-d7 dihydrochloride GW572016-dd₇ dihydrochloride; GW2016-dd₇ dihydrochloride	Isotope-Labeled Compounds EGFR Autophagy Ferroptosis	Cancer
Lapatinib-d₇ dihydrochloride is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898S4

Lapatinib-d7 GW572016-d₇; GW2016-d₇	Isotope-Labeled Compounds Autophagy EGFR Ferroptosis	Cancer
Lapatinib-d₇ (GW572016-d₇) is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898C

Lapatinib tosylate GW572016 tosylate; GW2016 tosylate	EGFR Ferroptosis Autophagy	Cancer
Lapatinib (GW572016) tosylate is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898CS

Lapatinib-d4 tosylate GW572016-d₄ tosylate; GW2016-d₄ tosylate	Isotope-Labeled Compounds EGFR Autophagy Ferroptosis	Cancer
Lapatinib-d₄ (GW572016-d₄) tosylate is deuterium labeled Lapatinib (tosylate). Lapatinib (GW572016) tosylate is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898S3

Lapatinib-d4-1 GW572016-d₄-1; GW2016-d₄-1	Isotope-Labeled Compounds EGFR Autophagy Ferroptosis	Cancer
Lapatinib-d₄-1 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898B

Lapatinib ditosylate monohydrate Maximum Cited Publications 81 Publications Verification GW572016 ditosylate monohydrate; GW2016 ditosylate monohydrate	EGFR Autophagy Ferroptosis	Cancer
Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898A

Lapatinib ditosylate Maximum Cited Publications 81 Publications Verification GW572016 ditosylate; GW2016 ditosylate	EGFR Autophagy Ferroptosis	Cancer
Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-P3498

Elsiglutide ZP1846	GCGR	Others
Elsiglutide (ZP1846) is a GLP-2 analogue, an orally active and selective GLP-2 receptor agonist, increases cell proliferation and reduces apoptosis in the intestine. Elsiglutide improves Lapatinib (HY-50898)-induced diarrhoea in rat model .

HY-131865

SJF-1521	PROTACs EGFR	Others
SJF-1521 is a selective EGFR PROTAC degrader. SJF-1521 contains the EGFR inhibitor lapatinib (HY-50898). SJF-1521 can induce EGFR degradation in OVCAR8 cells .

HY-125084

NEU617	Parasite	Infection
NEU617 is an anti-parasite agent. NEU617 inhibits the proliferation for the HAT (human African trypanosomiasis) pathogen (EC₅₀: 42 nM for Trypanosoma brucei, 1.8 μM for T. cruzi). NEU617 is a derivative of Lapatinib (HY-50898) .

HY-174414

EGFR/HER2-IN-18	EGFR	Cancer
EGFR/HER2-IN-18 is a stable EGFR/HER2 dual inhibitor with IC₅₀ values of 0.09 and 0.08 μM respectively. EGFR/HER2-IN-18 exhibits broad-spectrum anti-cancer activity. EGFR/HER2-IN-18 induces MCF-7 cells apoptosis and inhibits the cell cycle. EGFR/HER2-IN-18 can be used for the study of breast cancer .

HY-172970

HQY1428	CDK DNA/RNA Synthesis Apoptosis	Cancer
HQY1428 is an orally active CDK12 inhibitor. HQY1428 inhibits DNA replication, causes G2/M arrest in SKOV3 cells, induces DNA double-strand breaks and apoptosis. HQY1428 has anti-tumor activity in the SKOV3 xenograft mouse model. HQY1428 combined with the HER2 inhibitor Lapatinib (HY-50898) in the NCI-N87 xenograft mouse model produces a synergistic therapeutic effect .

HY-170922

SARS-CoV-2-IN-110	SARS-CoV	Infection
SARS-CoV-2-IN-110 (compound Bb1) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-110 exhibits antiviral efficacy against SARS-CoV-2 with an EC₅₀ of 1.10 μM and significantly lower toxicity compared to Lapatinib (HY-50898). SARS-CoV-2-IN-110 inhibits SARS-CoV-2 with a CC₅₀ of > 100 μM, with a selectivity index (SI) of >91 .

Cat. No.	Product Name	Target	Research Area

HY-P3498

Elsiglutide ZP1846	GCGR	Others
Elsiglutide (ZP1846) is a GLP-2 analogue, an orally active and selective GLP-2 receptor agonist, increases cell proliferation and reduces apoptosis in the intestine. Elsiglutide improves Lapatinib (HY-50898)-induced diarrhoea in rat model .

Cat. No.	Product Name	Chemical Structure

HY-50898S

Lapatinib-d4
Lapatinib-d₄ is the deuterium labeled Lapatinib (HY-50898). Lapatinib is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-W777297

Lapatinib-13C2,15N Ditosylate
Lapatinib- ¹³C₂, ¹⁵N Ditosylate is the ¹³C- and ¹⁵N-labeled Lapatinib ditosylate (HY-50898A). Lapatinib ditosylate (GW572016 ditosylate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-20390S

Lapatinib impurity 18-d4
Lapatinib impurity 18-d₄ is deuterium labeled 3-Chloro-4-((3-fluorobenzyl)oxy)aniline.

HY-50898S2

Lapatinib-d5
Lapatinib-d₅ is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898S1

Lapatinib-d7 dihydrochloride
Lapatinib-d₇ dihydrochloride is the deuterium labeled Lapatinib dihydrochloride. Lapatinib (GW572016) dihydrochloride is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898S4

Lapatinib-d7
Lapatinib-d₇ (GW572016-d₇) is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898CS

Lapatinib-d4 tosylate
Lapatinib-d₄ (GW572016-d₄) tosylate is deuterium labeled Lapatinib (tosylate). Lapatinib (GW572016) tosylate is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

HY-50898S3

Lapatinib-d4-1
Lapatinib-d₄-1 is deuterium labeled Lapatinib. Lapatinib (GW572016) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC₅₀ values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.